Orthopedic Oncology Fellowship (Guide) | Advanced Fellowship

What Is an Orthopedic Oncology Fellowship?

Orthopedic oncology is the surgical management of neoplastic disease affecting the musculoskeletal system. The scope is narrower than the word "oncology" implies but technically demanding in ways that distinguish it sharply from general orthopedic surgery. The core clinical problems are primary bone and soft-tissue sarcomas, metastatic skeletal disease, and benign but locally aggressive tumors. The defining technical challenge is limb salvage: removing a tumor with adequate margins while reconstructing load-bearing anatomy using endoprosthetic replacement, allograft, or combined biological-implant constructs.

Pelvic and sacral resections sit at the extreme of the operative spectrum — long cases with substantial blood loss, requiring command of vascular anatomy and multidisciplinary collaboration with general surgery, urology, and vascular surgery. Metastatic disease management, which constitutes a large share of daily volume at most programs, involves pathologic fracture fixation and prophylactic stabilization — less glamorous than limb salvage but clinically critical and heavily consulted.

What the fellowship trains you to do, specifically: operate on tumors that most orthopedic surgeons are not trained to treat, coordinate systemic therapy timing with surgical intervention, and function as the musculoskeletal specialist on a multidisciplinary tumor board. The non-operative cognitive load — staging workup interpretation, coordination with medical and radiation oncology, prognosis communication, and survivorship planning — is substantial and is trained alongside the operative curriculum.

The field is small by design. Annual fellowship output is limited, which maintains consistent demand for trained surgeons but also means the application environment is genuinely competitive.

Accreditation Status

Orthopedic oncology fellowships are not ACGME-accredited. This is a foundational fact every applicant must understand before engaging with the application process.

The oversight structure is specialty-society-based. The Musculoskeletal Tumor Society (MSTS) maintains a peer-review program recognition process that functions as the field's quality standard. Programs listed in the MSTS fellowship directory have been reviewed against society criteria, but this recognition is categorically different from ACGME institutional accreditation. There is no ACGME Program Requirements document, no ACGME Annual Program Evaluation cycle, and no ACGME-mandated case log minimum enforced by an external accreditor.

What this means in practice:

• Board eligibility: The American Board of Orthopaedic Surgery (ABOS) does not currently offer a separate subspecialty certificate in orthopedic oncology. Completion of fellowship does not confer independent board certification in the subspecialty. Surgeons practicing orthopedic oncology hold ABOS primary board certification through their residency pathway. The fellowship is a training credential and a market signal, not a path to a distinct certificate.
• Training credibility: MSTS recognition is the operative credentialing standard the field actually uses. Academic medical centers hiring orthopedic oncologists expect fellowship training at an MSTS-recognized program. The absence of ACGME accreditation does not diminish hiring-side expectations — it simply means the quality assurance mechanism is different.
• Supervision and protected time: Because ACGME duty-hour rules and supervision requirements do not apply, training conditions vary more across programs than they do in accredited residency. This is worth investigating program by program during interview season.
• Visa implications for international applicants: Non-ACGME fellowships do not qualify for J-1 Exchange Visitor sponsorship through ECFMG. This has significant implications for IMGs and international applicants. Verify current requirements directly with ECFMG/Intealth and official sources for your application year.

The accreditation status is not a reason to avoid the fellowship. It is operational information that shapes how you navigate credentialing, contracting, and immigration — and every applicant should understand it before the first application is submitted.

Fellowship Length and Structure

The standard format is 12 months. A small number of programs offer optional second-year research tracks, but the clinical fellowship is uniformly one year.

The core of training is operative experience on the orthopedic oncology service — tumor resections, limb-salvage reconstructions, metastatic disease stabilizations, and participation in complex pelvic cases. Most programs embed mandatory rotations that reflect the multidisciplinary nature of the field:

• Medical oncology: Typically one to four weeks, focused on systemic therapy sequencing, chemotherapy toxicity profiles relevant to surgical timing, and tumor board participation. The goal is functional fluency, not independent prescribing.
• Radiation oncology: Orientation to treatment planning, dose-volume relationships relevant to wound healing and bone remodeling, and indications for preoperative versus postoperative radiation in soft-tissue sarcoma.
• Musculoskeletal pathology: Direct time with pathologists reading bone and soft-tissue specimens, with emphasis on intraoperative frozen-section interpretation. This rotation has direct operative relevance — fellows who cannot communicate effectively with pathology during a case are at a meaningful disadvantage.
• Pediatric oncology: Varies substantially by program. Children's hospital-affiliated programs integrate pediatric exposure throughout; adult-cancer-center-based programs may concentrate it in a dedicated block. The biological and social differences in managing osteosarcoma in a 14-year-old versus a metastatic renal cell carcinoma in a 68-year-old are real, and exposure to both is the intended standard.

Case volume is a critical program-differentiation variable. MSTS survey data have documented meaningful variation across recognized programs in total sarcoma resections, endoprosthetic reconstructions, and pelvic cases performed during the fellowship year. When evaluating programs, ask specifically for case log data — not aggregate numbers but procedure-specific counts. Programs at high-volume NCI-designated cancer centers will typically offer more primary sarcoma exposure; programs at large general academic medical centers may offer more metastatic disease volume. Neither profile is inherently superior, but it should match your intended practice.

Prerequisites: What You Need Before Applying

The non-negotiable prerequisite is completion of an ACGME-accredited orthopedic surgery residency, or documented eligibility to complete one prior to fellowship start. You apply during residency — typically in your PGY-4 or PGY-5 year — and begin fellowship after residency graduation.

Beyond the structural prerequisite, the application package that programs actually evaluate includes:

• Board status: Most programs expect ABOS Part I (written examination) passage or eligibility at the time of application. Some programs weight board scores as a screening criterion; others do not. Confirm individual program expectations directly.
• Letters of recommendation: A letter from your residency program director is standard and expected. The highest-leverage additional letters come from orthopedic oncologists who can speak to your operative judgment and engagement with tumor cases, not from generalist attendings writing character references. If you have not rotated on a tumor service during residency, this is a material gap — addressable, but worth planning around early.
• Tumor rotation exposure: Residency programs vary in the quality and duration of orthopedic oncology rotations. Applicants who have operated on the tumor service, participated in tumor board, and can speak concretely to cases they have been part of are measurably stronger candidates than those with purely elective or observational exposure.
• Research output: Published or accepted manuscripts in oncologic surgery topics, abstracts presented at MSTS or related meetings, and documented IRB involvement all strengthen an application. This is discussed further in the research section below.

There is no formal minimum step score requirement published by MSTS. Individual programs set their own screening criteria, and some are more explicit than others. Ask directly.

How Many Programs Exist and Where They Are

Approximately 25 to 30 programs in the United States maintain active MSTS fellowship recognition at any given time. This number is not static — programs occasionally pause for leadership transitions or volume reasons — and the authoritative current list is the MSTS fellowship directory, which should be your first stop for program identification.

Geographic concentration follows the distribution of major cancer infrastructure. NCI-designated Comprehensive Cancer Centers and large academic medical centers account for the majority of recognized programs. This concentrates programs in metropolitan areas with established cancer networks: the Northeast corridor, major Midwest academic centers, large Texas and California academic systems, and a smaller number of programs in other regions. If geographic flexibility is limited, the program pool narrows quickly — this is a genuine constraint worth mapping early.

Some programs are embedded within children's hospitals or combined adult-pediatric cancer centers; others are purely adult-focused. The MSTS directory does not always make this distinction immediately obvious, and direct contact with program coordinators is the most reliable way to characterize each program's patient population mix.

Application Timeline and Process

Orthopedic oncology fellowship does not use SF Match. The MSTS administers its own match process, and the timeline differs from other subspecialty fellowship matches. See the current season timeline on the MSTS website for the active cycle's specific dates, as calendar details shift year to year.

The structural pattern, which has been consistent across recent cycles:

• Applications open and are submitted during the PGY-4 or early PGY-5 year of orthopedic surgery residency. This is earlier than some applicants expect — preparation work (research output, letter cultivation, rotation scheduling) needs to begin significantly before the application window opens.
• Interview invitations are issued by programs on a rolling or batch basis after the application deadline. Most interviews are conducted in a concentrated window, typically in late fall or early winter of the application year.
• A match day occurs on a date specified by MSTS for the cycle. Post-match scramble positions, when they exist, are filled independently.

Independent (outside-match) offers have historically occurred in orthopedic oncology at low but non-trivial rates — programs filling positions outside the formal match or offering positions very early to candidates with established relationships. The MSTS match agreement is intended to limit this, but applicants should understand the landscape as it actually operates rather than as the rules intend it to. Direct communication with program directors and mentors who know the current norms is more reliable than any static written guide on this point.

Applications are submitted through the MSTS application portal. The required components are program-standardized but typically include a personal statement, CV, medical school transcript, USMLE/COMLEX scores, board examination results, and letters of recommendation. Confirm the exact document list with each program before submitting, as requirements vary.

What Program Directors Look For

MSTS has published survey data on selection criteria, and the field is small enough that program director priorities are relatively well-characterized. The following reflects the documented hierarchy of factors across those surveys and the broader academic surgical training literature:

• Research output and productivity: Consistently rated among the top selection criteria. Publications in peer-reviewed journals, particularly in orthopedic oncology or related fields, are weighted heavily. Abstract presentations at MSTS or the American Academy of Orthopaedic Surgeons (AAOS) are meaningful. The operative reasoning behind this priority: orthopedic oncology is a small field sustained largely by academic practice, and programs are selecting trainees who will contribute to its evidence base.
• Tumor rotation experience during residency: Direct operative exposure to sarcoma and metastatic disease during residency — not merely elective observation — is consistently cited. Applicants who have scrubbed on limb-salvage cases, participated in tumor board presentations, and can discuss cases with specificity are distinguishable from those with purely peripheral exposure.
• Letter quality: A strong letter from a recognized orthopedic oncologist carries disproportionate weight in a field where most program directors know each other. A generic letter from a program director who cannot speak to oncologic surgical judgment adds little. This creates a clear incentive to build relationships with tumor surgeons during residency, ideally early enough to produce joint research.
• Personal statement: Programs are small — many have one or two fellows per year — and mission fit is weighted. A personal statement that articulates a specific career interest (pediatric tumor surgery, translational research, a particular reconstruction technique domain) is more useful to a program director than a generic statement of enthusiasm for the field.
• Interview performance: The interview is a mutual evaluation of fit in a close working environment. Programs are assessing collegiality, intellectual engagement with clinical problems, and whether the candidate can function as a representative of the program in multidisciplinary settings. See the interview preparation section below.

A note on operative technical skill: program directors generally assume applicants graduating from ACGME residency meet a baseline technical standard. Differentiating on the basis of "I am technically skilled" is less effective than differentiating on research productivity and demonstrable engagement with the intellectual content of oncologic surgery.

Surgical Skills and Case Milestones

The procedural core of fellowship training is built around competencies that are not addressed in standard orthopedic surgery residency. Fellows are expected to achieve independent operative capability — or near-independent capability under appropriate supervision — in the following domains by fellowship completion:

• Limb-salvage reconstruction for long-bone sarcomas: Distal femur, proximal tibia, proximal femur, proximal humerus, and diaphyseal resections with endoprosthetic replacement. Understanding of implant selection, fixation philosophy, and failure mode management.
• Allograft and allograft-prosthetic composite (APC) reconstruction: Biologic reconstruction alternatives to total endoprosthetic replacement, with understanding of union biology, resorption risk, and indication-based selection.
• Pelvic resections (Enneking-Dunham classifications I–IV): These are among the most technically demanding cases in musculoskeletal surgery. Full independence in all pelvic resection types by fellowship end is an ambitious target; operative judgment about patient selection and complication management is a realistic fellowship-level goal.
• Pathologic fracture fixation and prophylactic stabilization: Intramedullary nailing, plate fixation, and arthroplasty in the context of metastatic bone disease. Scoring systems for fracture risk (Mirels criteria and analogues) and decision-making about surgical versus non-surgical management.
• Amputation techniques: Above-knee, below-knee, hip disarticulation, and forequarter amputation — performed for tumor control rather than vascular disease, with different soft-tissue planning priorities.
• Intraoperative frozen-section interpretation: The ability to communicate directly with pathology about margin adequacy during a resection, interpret frozen-section results in clinical context, and make intraoperative decisions based on that information. This is a cognitive-operative skill distinct from reading a final pathology report.
• Soft-tissue sarcoma resection: Wide resection with margin planning, understanding of compartment anatomy, and coordination with plastic surgery for coverage when needed.

Case volume to achieve these competencies varies by procedure type and by program volume. This is a concrete question to ask on fellowship interviews: "What is the typical fellow case log at completion, broken down by procedure category?" Programs that cannot or will not answer this question specifically deserve follow-up scrutiny.

Research Expectations During Fellowship

Research is not peripheral to orthopedic oncology fellowship — it is structurally embedded in the training model at most MSTS-recognized programs. The expected outputs during a 12-month fellowship are demanding given the parallel clinical workload:

• IRB-approved study participation: Most fellows are expected to contribute to at least one ongoing or new IRB-approved study. At NCI-designated cancer centers, this may include participation in funded prospective trials. At smaller programs, it typically means retrospective cohort studies drawing on institutional databases.
• MSTS Annual Meeting presentation: Submitting an abstract and presenting at the MSTS annual meeting — either a podium presentation or poster — during or immediately after the fellowship year is a standard expectation. The MSTS meeting is the field's primary scientific forum and the professional network event that matters most for early-career positioning.
• Peer-reviewed manuscript submission: The realistic target for most fellows is one manuscript submitted for peer review by fellowship end, with publication following in the subsequent year. Some fellows with established research pipelines from residency will exceed this; fellows entering without prior manuscript experience may find this timeline tight.

How to position research during the application: the application is strengthened most by research that is already published or in press, secondarily by manuscripts under review, and then by work in progress with a clear timeline. Abstract presentations and conference posters are meaningful but are less weighted than peer-reviewed output. If you are a current resident reading this, the most actionable step is identifying an orthopedic oncologist at your program or a nearby institution and initiating a project with a defined question and dataset now, not during fellowship.

Fellowship program research infrastructure varies substantially. Programs embedded in NCI-designated cancer centers typically have dedicated research coordinators, institutional biostatistics support, and access to large prospective databases. Community-academic programs may offer more operative volume but less research scaffolding. If research productivity is central to your career goals — which it almost certainly needs to be if you are targeting academic orthopedic oncology — this variable should be weighted heavily in your rank list.

Compensation and Benefits

Because orthopedic oncology fellowships are not ACGME-accredited, stipends are not governed by institutional GME salary scales and vary more than they do in accredited training. Compensation is set by the sponsoring department or institution, and the range across programs is meaningful. See the PGY Zero compensation data page for current ranges rather than relying on figures in this text, which would become outdated rapidly.

Key structural points that are stable:

• NCI-designated cancer center programs may have access to T32 training grants or departmental research funding that supplements or replaces standard fellow stipend structures. Ask specifically whether fellowship support includes a grant component and what the associated research obligations are.
• Moonlighting is generally restricted or prohibited during fellowship, consistent with the time demands of the training. Non-ACGME status means there is no regulatory floor on work hours, but the practical workload at most programs leaves limited moonlighting capacity regardless of formal policy.
• Benefits packages — health insurance, malpractice coverage, conference travel support — vary by institution. Conference travel funding for MSTS meeting attendance is a reasonable item to ask about during the interview, since presenting at MSTS is an expected fellowship output and the travel cost is real.

Career Outcomes and Practice Settings

Orthopedic oncology is an academic-concentrated subspecialty. The field's case complexity and multidisciplinary infrastructure requirements mean that the majority of practicing orthopedic oncologists are based at academic medical centers, NCI-designated cancer centers, or large academic cancer networks. AAOS and MSTS workforce data have consistently reflected this distribution, with independent or community-based practice being the exception rather than the norm.

VA health system positions exist and provide a viable academic-adjacent practice environment for orthopedic oncologists, though volume varies by facility.

Demand drivers are real and structural. The aging of the US population increases the incidence of metastatic bone disease and the volume of pathologic fracture and stabilization cases — the highest-frequency component of orthopedic oncology practice. Primary sarcoma incidence is relatively stable, but the total burden of musculoskeletal tumor disease seen by orthopedic oncologists has grown. The field is small enough that individual program output matters to workforce supply.

For compensation benchmarks, MGMA and AAOS Orthopaedic Surgeon Census data are the primary published sources. See the PGY Zero compensation data page for current ranges and data year citations. The consistent finding across those surveys is that orthopedic oncology compensation is competitive within the orthopedic subspecialty spectrum, though the academic-heavy practice environment means base salaries are weighted more heavily than productivity-based RVU bonuses compared to procedurally intensive subspecialties in private practice settings.

Pediatric vs. Adult Orthopedic Oncology Track Considerations

Most MSTS-recognized fellowship programs train fellows across both pediatric and adult patient populations. The disease mix is genuinely different: pediatric orthopedic oncology is dominated by osteosarcoma and Ewing sarcoma — biologically aggressive primary bone tumors with established chemotherapy protocols — while adult orthopedic oncology includes a broader sarcoma histology spectrum plus substantial metastatic disease volume that is uncommon in pediatric practice.

Programs housed at or affiliated with children's hospitals will skew pediatric exposure significantly. Programs at adult cancer centers will provide the inverse. A combined adult-pediatric cancer center (which several MSTS-recognized programs are) offers the most balanced exposure.

How to decide which exposure mix fits your intended career:

• If your long-term goal is a position at a children's hospital or a predominantly pediatric tumor surgery practice, prioritize programs with substantial pediatric volume and relationships with pediatric oncology teams. These positions are scarce and the hiring network is tight — training at a program where the children's hospital relationship is strong is a meaningful career advantage.
• If your intended practice is adult academic orthopedic oncology at a cancer center, balanced or adult-heavy exposure is appropriate, and the emphasis on metastatic disease management volume is a practical asset.
• If you are uncertain, a balanced program gives more optionality. The pediatric-adult split is a harder thing to correct post-fellowship than most other training gaps.

Note that pediatric orthopedic surgery (ACGME-accredited) and pediatric orthopedic oncology are different pathways. Orthopedic oncology fellows are not completing a pediatric orthopedic fellowship and will not hold that credential. If pediatric musculoskeletal tumor surgery is the goal, orthopedic oncology fellowship — not pediatric orthopedic fellowship — is the correct training path.

How PGY-Zero Should Start Preparing Now

If you are a medical student reading this, the preparation horizon for orthopedic oncology fellowship is longer than it appears. The application occurs in residency, but the inputs that determine application strength — research output, operative exposure, letter relationships — are built over years, and the decisions you make in medical school shape what is available to you in residency.

Concrete, sequenced actions:

• Identify and rotate on a musculoskeletal tumor service in MS3 or MS4. Most medical schools have at least one orthopedic oncologist on faculty. A subinternship or extended elective on that service — where you attend tumor board, scrub on resections, and read staging workups — does two things simultaneously: it confirms your interest and it begins the relationship with a potential letter writer and research mentor.
• Choose orthopedic surgery as your specialty with the subspecialty goal stated early. Residency program directors at strong orthopedic programs are attuned to applicants with subspecialty focus. Stating orthopedic oncology as your intended subspecialty in your residency application personal statement is not limiting — it is a positioning signal that helps programs with active tumor services identify you as a good fit.
• Initiate a research relationship with an orthopedic oncologist before or early in residency. The most productive fellowship applications include publications, not just projects in progress. A project started in MS4 or PGY-1, with a defined question and a dataset that exists, can realistically reach submission by PGY-3 and publication by PGY-4 — precisely when the fellowship application is being assembled. Projects started in PGY-3 with the intention of having something to show for the application are often in the "manuscript in preparation" column, which is the least competitive category.
• Understand the fellowship-within-residency pipeline. Some orthopedic residency programs have established relationships with specific fellowship programs. Knowing which programs your residency has historically placed fellows into — and whether your program has an active tumor service that feeds into recognized fellowships — is information worth gathering before you commit to a residency program. This is a legitimate and appropriate question to ask residency program directors during residency interview season.
• Attend MSTS Annual Meeting as a student or early resident if possible. The meeting is small and the field is relationship-based. Presenting even a poster at MSTS as a resident positions you as someone who has already engaged with the community. This is not a networking strategy in the superficial sense — it means doing work that is worth presenting and taking it to the venue where the field's practitioners will see it.

The path to orthopedic oncology fellowship is long but the steps are legible. The bottleneck is not talent or even connections — it is the early, consistent accumulation of relevant experience and output that most applicants begin too late. Starting this preparation during medical school moves the probability distribution meaningfully in your direction.